Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-11-21
2006-11-21
Canella, Karen A. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387700, C530S388100, C530S388220, C530S388800, C530S388850
Reexamination Certificate
active
07138497
ABSTRACT:
Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two polypeptide chains, each of which define single-chain Fv (sFv) binding proteins and have C-terminal tails that facilitate the crosslinking of two sFv polypeptides. The resulting dimeric constructs have a conformation permitting binding of a said preselected antigen by the binding site of each said polypeptide chain when administered to said mammal. The formulation has particular utility in in vivo imaging and drug targeting experiments.
REFERENCES:
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4479930 (1984-10-01), Hnatowich
patent: 4753894 (1988-06-01), Frankel et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5132405 (1992-07-01), Huston et al.
patent: 5169774 (1992-12-01), Frankel et al.
patent: 5258498 (1993-11-01), Huston et al.
patent: 5260203 (1993-11-01), Ladner et al.
patent: 5571894 (1996-11-01), Wels et al.
patent: 5587458 (1996-12-01), King et al.
patent: 5629197 (1997-05-01), Ring et al.
patent: 5877305 (1999-03-01), Huston et al.
patent: 6054561 (2000-04-01), Ring
patent: 0502812 (1992-09-01), None
patent: WO85/03523 (1985-08-01), None
patent: WO88/09344 (1988-01-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO92/15682 (1992-09-01), None
patent: WO93/06217 (1993-04-01), None
patent: WO93/11161 (1993-06-01), None
patent: WO93/11162 (1993-06-01), None
patent: WO93/15210 (1993-08-01), None
patent: WO 93/16185 (1993-08-01), None
patent: WO 93/21319 (1993-10-01), None
patent: WO 88/09344 (1998-12-01), None
Rudikoff et al (Proc Natl Acad Sci USA 1982 vol. 79 p. 1979.
Colman (Research in Immunology 145:33-36, 1994.
Saul et al. (1978) The Journal of Biological Chemistry, vol. 253, No. 2, pp. 585-597, “Preliminary Refinement and Structural Analysis of the Fab Fragment from Human Immunoglobulin New at 2.0 A Resolution”.
Khav et al. (1980) Science, vol. 209, No. 4453, pp. 295-297, “Myocardial Infarct Imaging of Antibodies to Canine Cardiac Myosin with Indium-111-Diethylenetriamine Pentaacetic Acid”.
Kunkel (1985) Proc. Natl. Acad. Sci. vol. 82, pp. 488-492, “Rapid and efficient site-specific mutagenesis without phenotypic selection”.
Chen et al. (1985) DNA, vol. 4, No. 2, pp. 165-170, “Laboratory Methods Supercoil Sequencing: A Fast and Simple Method for Sequencing Plasmid DNA”.
Bjorn et al. (1985) Cancer Research, vol. 45, pp. 1214-1221, “Evaluation of Monocolonal Antibodies for the Development of Breast Cancer Immunotoxins”.
Fisher et al. (1986) Journal of Clinical Oncology, vol. 4, No. 6, pp. 929-941, “Ten-Year Results From the National Surgical Adjuvant Breast and Bowel Project (NSABP) Clinical Trial Evaluating the Use of L-Pheny-lalanine Mustard (L-PAM) in the Management of Primary Breast Cancer”.
Satow et al. (1986) J. Mol. Biol. , vol. 190, pp. 593-604, “Phosphocho-line Binding Immunoglubolin Fab McPC603 An X-ray Diffraction Study at 2.7 A”.
Amit et al. (1986) Science, vol. 233, pp. 747-753, “Three-Dimensional Structure of An Antigen-Antibody Complex at 2.8 A Resolution”.
Sheriff et al. (1987) Proc. Natl. Acad. Sci. USA, vol. 84, pp. 8075-8079, “Three-dimensional structure of an antibody-antigen complex”.
Colman et al. (1987) Nature, vol. 326, pp. 358-363, “Three-dimensional structure of a complex of antibody with influenza virus neuraminidase”.
Bartlet et al. (1987) The Lancet, vol. II, No. 8552, pp. 171-175, “Adjuvant Tamoxifen in the Management of Operable Breast Cancer: The Scottish Trial”.
Aisner et al. , (1987) Journal of Clinical Oncology, vol. 5, No. 10, pp. 1523-1533, “Chemotherapy Versus Chemoimmunotherapy (CAF v CAFVP v CMF Each ± MER) for Metastatic Carcinoma of the Breast : A CALGB Study”.
Huston et al. (1988) Proc. Natl. Acad. Sci. , Vo. 85, pp. 5879-5883, “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli”.
Sefton (1988) Trends in Genetics, vol. 4, No. 9, pp. 247-248, “neus about c-erb-B-2 and HER2”.
Bird, et al. (1988) Science, vol. 242, pp. 423-426, “Single-Chain Antigen-Binding Proteins”.
Vogel et al. (1988) Biochemistry, vol. 28, pp. 2961-2966, “Binding Domains and Epitopes in Platelet-Derived Growth Factor”.
Orlandi et al. (1989) Proc. Natl. Acad. Sci. USA, vol. 86, pp. 3833-3837, “Cloning immunoglobulin variable domains for expression by the polymerase chain reaction”.
Ring et al. (1989) Cancer Research vol. 49, No. 11, pp. 3070-3080, “Distribution and Physical Properties of BCA200, a M 200,000 Glyco-protein Selectively Associated with Human Breast Cancer”.
Dillman (1989), Annals of Internal Medicine, vol. 111, pp. 592-603, “Monoclonal Antibodies for Treating Cancer”.
Glockshuber et al. (1990) Biochemistry, vol. 29, pp. 1362-1367, “A Comparison of Strategies to Stabilize Immunoglobulin Fv-Fragments”.
Queen et al. (1989) Proc. Natl. Acad. Sci. , vol. 86, pp. 10029-10033, “A humanized antibody that binds to the interleukin 2 receptor”.
Hird et al. (1990) Genes and Cancer, pp. 183-189, “Immunotherapy with Monoclonal Antibodies”.
Batra et al. (1990) The Journal of Biological Chemistry, vol. 265, No. 25, pp. 15198-15202, “Anti-Tac (Fv)—PE40, a Single Chain Antibody Pseudomonas Fusion Protein Directed at Interleuken 2 Receptor Bearing Cells”.
McGuire et al. (1990) Journal of the National Cancer Institute, vol. 82 No. 12, pp. 1006-1015, “How to Use Prognostic Factors in Axillary Node-Negative Breast Cancer Patients”.
Shealy et al. (1990) The Journal of Nuclear Medicine, vol. 31, No. 5, Abstract Book Proceedings of the 37th Annual Meeting, “Characteriza- Characterization and Biodistribution of Tc-99m Labeled Single Chain Antibody Fv Fragment (sFv)”.
Colcher et al. (1990) J. Natl. Cancer Inst. , vol. 82, No. 14, pp. 1192-1197, “In Vivo Tumor Targeting of a Recombinant Single-Chain Antigen-Binding Protein”.
Batra et al. (1990) Biochemical and Biophysical Research Communications vol. 171, No. 1, pp. 1-6, “TGFa-anti-Tac (Fv)-PE40: A Bifunctional Toxin Cytotoxic for Cells with EGF or IL2 Receptors”.
Tai et al. (1990) Biochemistry, vol. 29, pp. 8024-8030, “A Bifunctional Fusion Protein Containing Fc-Binding Fragment of B of Staphylococcal Protein A Amino Terminal to Antidigoxin Single-Chain Fv”.
Huston et al. (1990) Bispecific Antibodies and Targeted Cellular Cyto-toxicity, Second International Conference, pp. 201-206, “Bifunctional Single-Chain Fv Fusion Proteins”.
Huston et al. (1990) Academic Press, Inc. , Methods in Enzymology, vol. 203, pp. 46-89, “Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins”.
Whitlow et al. (1991), Methods: A Companion to Methods in Enzymology, vol. 2, No. 2, pp. 97-105, “Single-Chain Fv Proteins and Their Fusion Proteins”.
Nedelman et al. (1991) Abstract Form for Scientific Papers, No. 32070 The Society of Nuclear Medicine 38th Annual Meeting, “Rapid Infarct Imaging with a New Tc-99m Antimyosin sFv Fragment: Evaluation in Acute Myocardial Infarction in Dogs”.
Waldmann (1991) Science, vol. 252, pp. 1657-1662, “Monoclonal Antibodies in Diagnosis and Therapy”.
Clackson et al. (1991) Nature, vol. 352, pp. 624-628, “Making antibody fragments using phage display libraries”.
Ring et al. (1991) Nature, vol. 28, No. 8, pp. 915-917, “Identity of BCA200 and c-erbB-2 Indicated by Reactivity of Monoclonal Antibodies with Recombinant c-erbB-2”.
Milenic et al. (1991) Cancer Research, vol.
Houston Lou L.
Ring David B.
Canella Karen A.
Chiron Corporation
Robins & Pasternak LLP
LandOfFree
Biosynthetic binding proteins for immuno-targeting does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biosynthetic binding proteins for immuno-targeting, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biosynthetic binding proteins for immuno-targeting will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3657660